Philippe Beuzeboc

12.8k total citations · 3 hit papers
243 papers, 7.6k citations indexed

About

Philippe Beuzeboc is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Philippe Beuzeboc has authored 243 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 136 papers in Pulmonary and Respiratory Medicine, 120 papers in Oncology and 63 papers in Surgery. Recurrent topics in Philippe Beuzeboc's work include Prostate Cancer Treatment and Research (89 papers), Cancer Treatment and Pharmacology (44 papers) and Bladder and Urothelial Cancer Treatments (38 papers). Philippe Beuzeboc is often cited by papers focused on Prostate Cancer Treatment and Research (89 papers), Cancer Treatment and Pharmacology (44 papers) and Bladder and Urothelial Cancer Treatments (38 papers). Philippe Beuzeboc collaborates with scholars based in France, United States and United Kingdom. Philippe Beuzeboc's co-authors include P Pouillart, Stéphane Oudard, Thierry Dorval, Bernard Asselain, Suzy Scholl, Karim Fizazi, M Jouve, Jean‐Yves Pierga, T Palangié and J.C. Durand and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Philippe Beuzeboc

228 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

2012 420 citations Philippe Beuzeboc et al. profile →
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

2021 351 citations Scott T. Tagawa, Arjun Vasant Balar et al. Journal of Clinical Oncology profile →
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

2015 315 citations Gwénaëlle Gravis, Jean-Marc Ferrero et al. European Urology profile →

Peers

Countries citing papers authored by Philippe Beuzeboc

Since Specialization

Citations

This map shows the geographic impact of Philippe Beuzeboc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Beuzeboc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Beuzeboc more than expected).

Fields of papers citing papers by Philippe Beuzeboc

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Beuzeboc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Beuzeboc. The network helps show where Philippe Beuzeboc may publish in the future.

Co-authorship network of co-authors of Philippe Beuzeboc

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Beuzeboc. A scholar is included among the top collaborators of Philippe Beuzeboc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Beuzeboc. Philippe Beuzeboc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparison of PERCIST5, imPERCIST5, and PERCIMT Criteria for Early Assessment of Pembrolizumab Response with FDG-PET/CT in Metastatic Bladder Cancer Patients 2025 ·Pharmaceuticals ·(unknown), (unknown), C. Radulescu, Philippe Beuzeboc, C. Landais, (unknown), Christine L. Abraham, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Romain‐David Seban, (unknown)	0
2	Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial 2025 ·European Urology ·Matthew D. Galsky, Michiel S. van der Heijden, Thomas Powles, Mélanie Claps, Mauricio Burotto, Michael Schenker, Juan Pablo Sade, Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, Yüksel Ürün, Dingwei Ye, Begoña P. Valderrama, Yoshihiko Tomita, Ruiyun Jiang, Jeiry Filian, Lily Wang, (unknown), Guru Sonpavde	0
3	Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial. 2024 ·Journal of Clinical Oncology ·Matt D. Galsky, Guru Sonpavde, Thomas Powles, Mélanie Claps, Mauricio Burotto, Michael Schenker, Juan Pablo Sade, Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, Yüksel Ürün, Dingwei Ye, Begoña P. Valderrama, Yoshihiko Tomita, Jeiry Filian, Lily Wang, Daniela Purcea, Michiel Simon Van Der Heijden	11
4	A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer 2024 ·Future Oncology ·Yohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, Rohit Jain, Sumati Gupta, Manojkumar Bupathi, Philippe Beuzeboc, Phillip L. Palmbos, Arjun Vasant Balar, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Julia Tonelli, (unknown), (unknown), Petros Grivas, Philippe Barthélémy, Rick Bangs, Scott T. Tagawa	1
5	Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer 2024 ·International Journal of Molecular Sciences ·Emmanuel Chamorey, (unknown), Jean-Marc Ferrero, Hakim Mahammedi, Gwénaëlle Gravis, Guilhem Roubaud, Philippe Beuzeboc, Rémy Largillier, (unknown), Claude Linassier, (unknown), Marie-Christine Étienne-Grimaldi, Renaud Schiappa, Jocelyn Gal, G. Milano	0
6	LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial 2023 ·Annals of Oncology ·Michiel S. van der Heijden, Guru Sonpavde, Thomas Powles, Andrea Necchi, Mauricio Burotto, Michael Schenker, (unknown), Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, (unknown), (unknown), Zhisong He, Begoña P. Valderrama, (unknown), (unknown), Daniela Purcea, Federico Nasroulah, Matt D. Galsky	9
7	Vaccination against HPV: Easier said than done? 2023 ·Human Vaccines & Immunotherapeutics ·Henri‐Corto Stoeklé, (unknown), (unknown), Jaafar Bennouna, Philippe Beuzeboc, Christian Hervé	0
8	Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer 2023 ·Pharmaceutics ·Jean-Marc Ferrero, Hakim Mahammedi, Gwénaëlle Gravis, Guilhem Roubaud, Philippe Beuzeboc, (unknown), Delphine Borchiellini, Claude Linassier, Nathalie Ebran, (unknown), Marie-Christine Étienne-Grimaldi, Renaud Schiappa, Jocelyn Gal, G. Milano	3
9	Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study 2022 ·Current Oncology ·(unknown), Alexandre Vallée, (unknown), (unknown), Brigitte Bonan, Christine L. Abraham, Philippe Beuzeboc, Raffaele Ratta	6
10	Bio‐ethical issues in oncology during the first wave of the COVID‐19 epidemic: A qualitative study in a French hospital 2022 ·Journal of Evaluation in Clinical Practice ·Henri‐Corto Stoeklé, (unknown), (unknown), Philippe Beuzeboc, Christian Hervé	1
11	The Supportive Care sCore (SCC): trigger alert validation study in solid tumours 2021 ·BMJ Supportive & Palliative Care ·(unknown), (unknown), Julia Salleron, Philippe Beuzeboc, Florian Scotté	1
12	PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review 2020 ·Prostate Cancer and Prostatic Diseases ·Raffaele Ratta, Annalisa Guida, Florian Scotté, Y. Neuzillet, (unknown), Thierry Lebrét, Philippe Beuzeboc	30
13	Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review 2017 ·European Urology Focus ·Pierre‐Jean Lamy, Yves Allory, Anne‐Sophie Gauchez, Bernard Asselain, Philippe Beuzeboc, Patricia de Crémoux, Jacqueline Fontugne, (unknown), Christophe Hennequin, Jacqueline Lehmann‐Che, Christophe Massard, Ingrid Millet, T. Murez, Marie‐Hélène Schlageter, Olivier Rouvière, Diana Kassab‐Chahmi, François Rozet, Jean‐Luc Descotes, Xavier Rébillard	59
14	Radium 223 dichloride for prostate cancer treatment 2017 ·Drug Design Development and Therapy ·Emmanuel Deshayes, M. Roumiguié, Constance Thibault, Philippe Beuzeboc, F. Cachin, Christophe Hennequin, D. Huglo, François Rozet, Diana Kassab‐Chahmi, Xavier Rébillard, Nadine Houédé	68
15	[Reflexion on innovation diffusion factors: the case of Herceptin]. 2007 ·PubMed ·(unknown), (unknown), Anne Vincent‐Salomon, J. Couturier, Philippe Beuzeboc, Alain Livartowski	1
16	[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance]. 2007 ·PubMed ·Véronique Dièras, Anne Vincent‐Salomon, Armelle Degeorges, Philippe Beuzeboc, L. Mignot, Patricia de Crémoux	14
17	Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c- erb b-2) status in urothelial carcinoma 2004 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Gonzague de Pinieux, (unknown), Anne Vincent‐Salomon, (unknown), Delphine Amsellem‐Ouazana, Philippe Beuzeboc, Annick Vieillefond	24
18	[Targeting epidermal growth factor receptor in cancer of the breast]. 2003 ·PubMed ·(unknown), (unknown), Anne Vincent‐Salomon, Philippe Beuzeboc, P Pouillart, (unknown)	4
19	Concomitant pelvic irradiation and chemotherapy in locally advanced cervical carcinoma. A retrospective study of 92 patients treated at the Curie Institute 2002 ·Cancer/Radiothérapie ·L. Chauveinc, (unknown), J.M. Cosset, Anne de la Rochefordière, (unknown), (unknown), (unknown), Philippe Beuzeboc	2
20	Infiltrating lobular carcinoma of the breast: Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns 1996 ·Cancer ·Xavier Sastre‐Garau, Michel Jouve, Bernard Asselain, Anne Vincent-Salomon, Philippe Beuzeboc, Thierry Dorval, J.C. Durand, (unknown), P Pouillart	327

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact